{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T12:03:29Z","timestamp":1785499409496,"version":"3.56.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10637-026-01607-1","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:41:38Z","timestamp":1772880098000},"page":"113-120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic factors and outcome measures after BRAF-directed targeted therapy of unresectable metastatic BRAFV600E colorectal cancer: a study cohort-level analysis"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0903-6793","authenticated-orcid":false,"given":"Giuseppe A.","family":"Colloca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8793-8138","authenticated-orcid":false,"given":"Antonella","family":"Venturino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"issue":"3","key":"1607_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"key":"1607_CR2","first-page":"1","volume":"42","author":"J Tabernero","year":"2022","unstructured":"Tabernero J, Ros J, Elez E (2022) The evolving treatment landscape in BRAF-V600E-mutated metastatic colorectal cancer. Am Soc Clin Oncol Educ Book 42:1\u201310","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"28","key":"1607_CR3","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1200\/JCO.20.01225","volume":"38","author":"C Cremolini","year":"2020","unstructured":"Cremolini C, Antoniotti C, Stein A, Bendell J, Gruenberger T, Rossini D et al (2020) Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol 38(28):3314\u20133324","journal-title":"J Clin Oncol"},{"issue":"17","key":"1607_CR4","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T et al (2019) Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med 381(17):1632\u20131643","journal-title":"N Engl J Med"},{"issue":"1","key":"1607_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/annonc\/mdp523","volume":"21","author":"ED Saad","year":"2010","unstructured":"Saad ED, Katz A, Hoff PM, Buyse M (2010) Progression-free survival as surrogate and as true end point: insight from the breast and colorectal cancer literature. Ann Oncol 21(1):7\u201312","journal-title":"Ann Oncol"},{"issue":"33","key":"1607_CR6","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1200\/JCO.2007.11.8836","volume":"25","author":"M Buyse","year":"2007","unstructured":"Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL et al (2007) Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 25(33):5218\u20135224","journal-title":"J Clin Oncol"},{"issue":"11","key":"1607_CR7","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1002\/1097-0142(20010601)91:11<2033::AID-CNCR1229>3.0.CO;2-J","volume":"91","author":"C Louvet","year":"2001","unstructured":"Louvet C, de Gramont A, Tournigand C, Artru P, Maindrault-Goebel F, Krulik M (2001) Correlation between progression-free survival and response rate in patients with metastatic colorectal carcinoma. Cancer 91(11):2033\u20132038","journal-title":"Cancer"},{"issue":"29","key":"1607_CR8","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1200\/JCO.2006.08.1935","volume":"25","author":"PA Tang","year":"2007","unstructured":"Tang PA, Bentzen SM, Chen EX, Siu LL (2007) Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 25(29):4562\u20134568","journal-title":"J Clin Oncol"},{"issue":"9","key":"1607_CR9","first-page":"3595","volume":"61","author":"CK Weber","year":"2001","unstructured":"Weber CK, Slurpsky JR, Kalmes HA, Rapp UR (2001) Active Ras induces heterodimerization of cRaf and Braf. Cancer Res 61(9):3595\u20133598","journal-title":"Cancer Res"},{"issue":"9","key":"1607_CR10","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1002\/ijc.32320","volume":"145","author":"H Osumi","year":"2019","unstructured":"Osumi H, Shinozaki E, Wakatsuki T, Suenaga M, Ichimura T, Ogura M et al (2019) Non-V600E BRAF mutations and EGFR signaling pathways in colorectal cancer. Int J Cancer 145(9):2488\u20132495","journal-title":"Int J Cancer"},{"issue":"1","key":"1607_CR11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/1078-0432.CCR-16-0140","volume":"23","author":"D Barras","year":"2017","unstructured":"Barras D, Missiaglia E, Wirapati P, Sieber OM, Jorissen RN, Love C et al (2017) BRAF V600E mutant colorectal cancer subtypes based on gene expression. Clin Cancer Res 23(1):104\u2013115","journal-title":"Clin Cancer Res"},{"key":"1607_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2019.06.008","volume":"118","author":"F Loupakis","year":"2019","unstructured":"Loupakis F, Intini R, Cremolini C, Orlandi A, Sartore-Bianchi A, Pietrantonio F et al (2019) A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the \u2018BRAF becool\u2019 study. Eur J Cancer 118:121\u2013130","journal-title":"Eur J Cancer"},{"issue":"11","key":"1607_CR13","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney J, Dienstmann R, Wang X, de Reyni\u00e8s A, Schlicker A, Soneson C et al (2015) The consensus molecular subtypes of colorectal cancer. Nat Med 21(11):1350\u20131356","journal-title":"Nat Med"},{"key":"1607_CR14","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","volume":"392","author":"E Elez","year":"2025","unstructured":"Elez E, Yoshino T, Shen L, Lonardi S, Van Cutsem E, Eng C et al (2025) Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer. N Engl J Med 392:2425\u20132437","journal-title":"N Engl J Med"},{"issue":"11","key":"1607_CR15","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1038\/s41591-024-03235-9","volume":"30","author":"S Kopetz","year":"2024","unstructured":"Kopetz S, Murphy DA, Pu J, Ciardiello F, Desai J, Van Cutsem E et al (2024) Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial. Nat Med 30(11):3261\u20133271","journal-title":"Nat Med"},{"key":"1607_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.705060","volume":"9","author":"S Cen","year":"2021","unstructured":"Cen S, Liu K, Zheng Y, Shan J, Jing C, Gao J et al (2021) BRAF mutation as a potential therapeutic target for checkpoint inhibitors: a comprehensive analysis of immune microenvironment in BRAF mutated colon cancer. Front Cell Dev Biol 9:705060","journal-title":"Front Cell Dev Biol"},{"key":"1607_CR17","first-page":"660","volume":"6","author":"CN Clarke","year":"2015","unstructured":"Clarke CN, Kopetz ES (2015) BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. J Gastrointest Oncol 6:660\u2013667","journal-title":"J Gastrointest Oncol"},{"key":"1607_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JAC Sterne","year":"2016","unstructured":"Sterne JAC, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Br Med J 355:i4919","journal-title":"Br Med J"},{"key":"1607_CR19","doi-asserted-by":"publisher","unstructured":"Colloca GA, Venturino A (2024) Colorectal cancer. In: The prognosis of metastatic gastrointestinal cancer, 1st edn. CRC Press. https:\/\/doi.org\/10.1201\/9781032703350","DOI":"10.1201\/9781032703350"},{"key":"1607_CR20","unstructured":"The jamovi project (2024) jamovi. (Version 2.6) [Computer Software]. Retrieved from https:\/\/www.jamovi.org"},{"issue":"34","key":"1607_CR21","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","volume":"33","author":"S Kopetz","year":"2015","unstructured":"Kopetz S, Desai J, Chan E, Hecht JR, O\u2019Dwyer PJ, Maru D et al (2015) Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol 33(34):4032\u20134038","journal-title":"J Clin Oncol"},{"issue":"4","key":"1607_CR22","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","volume":"8","author":"RB Corcoran","year":"2018","unstructured":"Corcoran RB, Andr\u00e8 T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC et al (2018) Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer. Cancer Discov 8(4):428\u2013443","journal-title":"Cancer Discov"},{"issue":"4","key":"1607_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.20.01994","volume":"39","author":"S Kopetz","year":"2021","unstructured":"Kopetz S, Guthrie KA, Morris VK, Lenz H-J, Magliocco AM, Maru D et al (2021) Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). J Clin Oncol 39(4):285\u2013294","journal-title":"J Clin Oncol"},{"key":"1607_CR24","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00191","volume":"6","author":"KA Klute","year":"2022","unstructured":"Klute KA, Rothe M, Garrett-Mayer E, Mangat PK, Nazemzadeh R, Yost KJ et al (2022) Cobimetinib plus vemurafenib in patients with colorectal cancer with BRAF mutations: results from the targeted agent and profiling utilization registry (TAPUR) study. JCO Precis Oncol 6:e2200191","journal-title":"JCO Precis Oncol"},{"key":"1607_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejca.2021.12.028","volume":"163","author":"Z Wang","year":"2022","unstructured":"Wang Z, Qin BD, Ye CY, Wang MM, Yuan LY, Dai WP et al (2022) Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil\/leucovorin\/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): an open-label, single-arm, phase II trial. Eur J Cancer 163:152\u2013162","journal-title":"Eur J Cancer"},{"issue":"3","key":"1607_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100506","volume":"7","author":"A Boccaccino","year":"2022","unstructured":"Boccaccino A, Borelli B, Intini R, Antista M, Bensi M, Rossini D et al (2022) Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. ESMO Open 7(3):100506","journal-title":"ESMO Open"},{"key":"1607_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejca.2022.03.011","volume":"168","author":"E Hafliger","year":"2022","unstructured":"Hafliger E, Boccaccino A, Lapeyre-Prost A, Perret A, Gallois C, Antista M et al (2022) Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: an AGEO-GONO case series. Eur J Cancer 168:34\u201340","journal-title":"Eur J Cancer"},{"issue":"14","key":"1607_CR28","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1200\/JCO.22.01693","volume":"41","author":"E Van Cutsem","year":"2023","unstructured":"Van Cutsem E, Taieb J, Yaeger R, Yoshino T, Grothey A, Maiello E et al (2023) ANCHOR CRC: results from a single arm, phase II study of encorafenib plus binimetinib and cetuximab in previously untreted BRAFV600E-mutant metastatic colorectal cancer. J Clin Oncol 41(14):2628\u20132637","journal-title":"J Clin Oncol"},{"issue":"6","key":"1607_CR29","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.annonc.2023.02.016","volume":"34","author":"J Ros","year":"2023","unstructured":"Ros J, Matito J, Villacampa G, Comas R, Garcia A, Martini G et al (2023) Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Ann Oncol 34(6):543\u2013552","journal-title":"Ann Oncol"},{"issue":"9","key":"1607_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103696","volume":"9","author":"C Gallois","year":"2024","unstructured":"Gallois C, Bergen ES, Auclin E, Pernot S, Higu\u00e8 J, Trouilloud I et al (2024) Efficacy and safety of the combination of encorafenib\/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study. ESMO Open 9(9):103696","journal-title":"ESMO Open"},{"issue":"2","key":"1607_CR31","first-page":"174","volume":"23","author":"D Kotani","year":"2024","unstructured":"Kotani D, Takashima A, Kato T, Satoh T, Masuishi T, Komatsu Y et al (2024) Safety and efficacy of encorafenib, binimetinib, and cetuximab for BRAFV600E-mutant metastatic colorectal cancer: results of the Japanese expanded access program. Clin Colorectal Cancer 23(2):174\u201382.e6","journal-title":"Clin Colorectal Cancer"},{"key":"1607_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114290","volume":"210","author":"M Ambrosini","year":"2024","unstructured":"Ambrosini M, Tougeron D, Modest D, Guimbaud R, Kopetz S, Decraecker M et al (2024) BRAF + EGFR +\/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer. Eur J Cancer 210:114290","journal-title":"Eur J Cancer"},{"issue":"12","key":"1607_CR33","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1038\/s41416-024-02696-6","volume":"130","author":"AH Ree","year":"2024","unstructured":"Ree AH, Saltyte Benth J, Hamre HM, Kersten C, Hofsli E, Guren MG et al (2024) First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer \u2013 the randomized METIMMOX trial. Br J Cancer 130(12):1921\u20131928","journal-title":"Br J Cancer"},{"issue":"1","key":"1607_CR34","doi-asserted-by":"publisher","first-page":"2372886","DOI":"10.1080\/2162402X.2024.2372886","volume":"13","author":"AH Ree","year":"2024","unstructured":"Ree AH, Hoye E, Esbensen Y, Beitnes AR, Negard A, Bernklev L et al (2024) Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade. Oncoimmunology 13(1):2372886","journal-title":"Oncoimmunology"},{"key":"1607_CR35","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221105022","volume":"14","author":"T Xu","year":"2022","unstructured":"Xu T, Wang X, Wang Z, Deng T, Qi C, Liu D et al (2022) Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR\/BRAF inhbitors. Ther Adv Med Oncol 14:17588359221105022","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"1607_CR36","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/2326-6066.CIR-13-0160","volume":"2","author":"MK Callahan","year":"2014","unstructured":"Callahan MK, Masters G, Pratilas CA, Ariyan C, Katz J, Kitano S et al (2014) Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunol Res 2(1):70\u201379","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"1607_CR37","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","volume":"21","author":"L Liu","year":"2015","unstructured":"Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T et al (2015) The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res 21(7):1639\u20131651","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1607_CR38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41590-020-00818-9","volume":"22","author":"V Verma","year":"2021","unstructured":"Verma V, Jafarzadeh N, Boi S, Kundu S, Jiang Z, Fan Y et al (2021) MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects. Nat Immunol 22(1):53\u201366","journal-title":"Nat Immunol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01607-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01607-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01607-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:41:16Z","timestamp":1785498076000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-026-01607-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1607"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01607-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any interventional studies with human participants, human data, or human tissue performed by any of the authors.","order":1,"name":"Ethics","label":"Ethics approval, informed consent, and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}